About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | STA-5326 in Crohn's Disease Patients

STA-5326 in Crohn's Disease Patients

NCT00088062·18 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Synta Pharmaceuticals Corp.

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients 18-65 years old
Crohn's Disease for 6 months
CDAI scores between 220-450
+/- 5-ASA, stable dose for \> 2 weeks
+/- Corticosteroids, less than or equal to 40 mg per day with a stable dose for 2 weeks
+/- Infliximab with no treatment within 4 weeks
+/- 6-Mercaptopurine, with a stable dose for 8 weeks
+/- Antibiotics, with a stable dose for 2 weeks

You may not be if

Patients who have had methotrexate, cyclosporine, or other experimental drug within 3 months of screening
Pregnancy, breast feeding
History of total proctocolectomy with stoma. Previous ileocolectomy would not be a contraindication to the study
Bowel obstruction
Surgical bowel resection within 90 days
Total parenteral nutrition (TPN), CYA, tacrolimus

The record

StatusCompleted

PhasePhase 1–2

Taking part48

StartedFeb 2004

UpdatedJun 24, 2005

Conditions

Crohn's Disease

Where18

Advanced Clinical Therapeutics
Tucson, Arizona, United States
Advanced Clinical Research Institute
Anaheim, California, United States
Venture Research Institute, LLC
North Miami Beach, Florida, United States